Beijing Wantai Biological Pharmacy Enterprise Co Ltd

603392.CG

Wus Printed Circuit and Jiangxi Copper first-half net profits rise 73.72% and 106.77% respectively

Wus Printed Circuit, Jiangxi Copper and several other companies released their 2026 semi-annual reports. Wus Printed Circuit's first-half net profit rose 73.72% year on year, while Jiangxi Copper's net profit rose 106.77%. Huashengchang's first-half net profit grew 73%, with second-quarter net profit up 223% quarter on quarter. JPT's 2026 semi-annual net profit rose 105.25% year on year. Naura Technology's first-half net profit rose 5.05% year on year. In addition, Zhong Shanshan, the actual controller of Wantai Biological Pharmacy, donated 33 million company shares free of charge to the Fujian Xiang'an Innovation Laboratory Science and Technology Development Foundation, accounting for 2.61% of the company's total share capital.

002371.CS ▲002463.CS ▲600362.CG ▲688025.CG ▲603392.CG

21世纪经济·3dRead more ▾

603392.CG▼

Wantai Biological Pharmacy reports net loss of 128 million yuan in 2026 interim report

Wantai Biological Pharmacy released its 2026 interim report, showing a net loss attributable to the parent company of 128 million yuan, narrowing the loss by 15.72 million yuan compared with the same period last year. Total operating revenue was 1.048 billion yuan, up 24.29 percent year on year. Net cash outflow from operating activities was 81.32 million yuan, an increase of 14.77 million yuan from a year earlier. The company's latest gross margin was 63.91 percent, up 3.56 percentage points from the same period last year.

603392.CG ▼

Jiemian·7dRead more ▾

603392.CG▼

Wantai Biological Pharmacy reports net loss of 128 million yuan in 2026 interim report

Wantai Biological Pharmacy released its 2026 interim report, with net profit attributable to the parent company at minus 128 million yuan. Total operating revenue was 1.048 billion yuan, and net cash flow from operating activities was minus 81.32 million yuan, a decrease of 14.77 million yuan compared with the same period last year. The latest asset-liability ratio was 13.17 percent, gross margin was 63.91 percent, return on equity was minus 1.09 percent, and diluted earnings per share was minus 0.10 yuan.

603392.CG ▼

Jiemian·7dRead more ▾

Biotech & Genomic Medicine▲

Wantai Biological's Nine-Valent HPV Vaccine Receives Marketing Approval in Thailand

Xiamen Innovax Biotech, a wholly owned subsidiary of Wantai Biological, has received approval from the Thai Food and Drug Administration to market its independently developed nine-valent HPV vaccine. The vaccine is indicated for females aged 9 to 45 and covers seven high-risk HPV types—16, 18, 31, 33, 45, 52, and 58—as well as two low-risk types, 6 and 11. Earlier, the vaccine was approved by China's National Medical Products Administration in 2025, becoming the first domestically developed nine-valent HPV vaccine and the second globally.

603392.CG ▲

Biotech & Genomic Medicine ▲

Jiemian·15dRead more ▾

Biotech & Genomic Medicine▲

Wantai Biological's Freeze-Dried Recombinant RSV Vaccine Clinical Trial Application Accepted

The clinical trial application for the freeze-dried recombinant respiratory syncytial virus vaccine, CHO cell, submitted by Xiamen Wantai Canghai Biotechnology, a wholly owned subsidiary of Wantai Biological, has been accepted by the National Medical Products Administration. The vaccine is jointly developed by Xiamen Wantai Canghai and Xiamen University, using genetic engineering recombinant technology and produced with CHOZN cells. Its main active ingredient is an independently developed RSV prefusion conformation membrane fusion protein F, formulated as an adjuvant-free freeze-dried product. Preclinical data show good safety, and it can induce RSV-specific protective immune responses in animals such as mice and cotton rats.

603392.CG ▲

Biotech & Genomic Medicine

Jiemian·38dRead more ▾

603392.CG▼3

Wantai Biological Pharmacy General Manager Jiang Zhiming Resigns After Less Than Three Years, Annual Salary 3.24 Million Yuan

Wantai Biological Pharmacy General Manager Jiang Zhiming has resigned for personal reasons, having served less than three years. She took up the general manager role in January 2024, with an original term running to April 2027, and her 2025 pre-tax compensation was 3.2416 million yuan. As the company's 2025 loss widened to 398 million yuan, marking its first loss since listing, Jiang and other senior executives voluntarily gave up their 2025 performance bonuses. Chairman Qiu Zixin will assume the duties of general manager, and the company is working to select a successor as soon as possible. Wantai Biological Pharmacy's nine-valent HPV vaccine has been launched but has yet to generate scaled profits. In the first quarter of 2026, revenue grew 30.6 percent, and the loss narrowed to 42.98 million yuan.

603392.CG ▼

澎湃新闻·54dRead more ▾

603392.CG▼4

Wantai Biological's Director and General Manager Resigns, Chairman Assumes General Manager Duties

Wantai Biological announced that Director and General Manager Ms. JIANG ZHIMING has resigned from her positions as director, general manager, and member of the Strategy and Sustainable Development Committee and the Nomination Committee due to personal reasons. The resignation takes effect upon delivery to the board of directors, and she will no longer hold any position in the company. The company held the 17th meeting of the sixth board of directors on July 3, where it approved Chairman Mr. Qiu Zixin to assume the duties of general manager.

603392.CG ▼

Jiemian·55dRead more ▾